Physician profile
Gerald Keneth Hill
NPI 1114971009
$5,680.32
in general payments reported to CMS, 2019-2025
46 companies · $334 in 2025
The $334 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $1,131 · 2020: $806 · 2021: $1,055 · 2022: $1,107 · 2023: $841 · 2024: $406 · 2025: $334.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,581.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,580.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $546.33 | 2019-2025 | Farxiga, Breztri |
| Novo Nordisk INC | $468.74 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $418.01 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $369.34 | 2019-2025 | Jardiance, Tradjenta |
| Sanofi-Aventis U.S. LLC | $345.16 | 2019-2023 | |
| Sunovion Pharmaceuticals INC. | $334.88 | 2019-2022 | |
| Glaxosmithkline, LLC. | $331.73 | 2019-2024 | Trelegy Ellipta, Shingrix |
| Novartis Pharmaceuticals Corporation | $307.02 | 2019-2024 | |
| Abbvie INC. | $285.32 | 2019-2023 | |
| Astellas Pharma US INC | $184.46 | 2019-2024 | Veozah |
| Preventric Diagnostics, INC. | $156.08 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $135.04 | 2019-2022 | |
| Xeris Pharmaceuticals, INC. | $119.19 | 2021-2023 | Gvoke Hypopen |
| Kowa Pharmaceuticals America, INC. | $104.07 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $103.89 | 2019-2023 | Xarelto |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $100.81 | 2021-2022 | |
| Arbor Pharmaceuticals, INC. | $98.56 | 2019-2021 | |
| Pfizer INC. | $98.19 | 2019-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $97.66 | 2019-2021 | |
| Lilly USA, LLC | $97.27 | 2020-2022 | |
| Shield Therapeutics INC | $89.98 | 2023-2025 | Accrufer |
| Amarin Pharma, INC. | $83.02 | 2019-2021 | |
| Corcept Therapeutics | $74.36 | 2024-2025 | Korlym |
| Sumitomo Pharma America, INC. | $59.21 | 2023-2024 | Gemtesa |
| Biohaven Pharmaceutical Holding Company LTD. | $58.81 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $54.23 | 2023-2024 | Nuedexta, Rexulti |
| Abbott Laboratories | $53.07 | 2022 | |
| Mylan Specialty L.P. | $51.18 | 2024 | Yupelri |
| Amgen INC. | $49.19 | 2022-2024 | Tavneos, Otezla, Repatha |
| Ironwood Pharmaceuticals, INC | $42.56 | 2021-2023 | Linzess |
| Merck Sharp & Dohme LLC | $41.91 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $40.20 | 2021 | |
| Azurity Pharmaceuticals, INC. | $36.34 | 2022-2023 | Edarbyclor |
| Medtronic, INC. | $32.51 | 2021-2024 | Intellis Adaptivestim |
| Avanir Pharmaceuticals, INC. | $28.41 | 2022 | |
| Lundbeck LLC | $25.21 | 2025 | Rexulti |
| Hologic Sales and Service, LLC | $21.36 | 2025 | Aptima |
| Corium, LLC | $20.46 | 2023 | Adlarity |
| Dexcom, INC. | $19.66 | 2025 | Dexcom G6 Transmitter |
| Allergan, INC. | $16.65 | 2020 | |
| Inspire Medical Systems, INC. | $15.87 | 2025 | Inspire |
| Medtronic Minimed, INC. | $15.39 | 2019 | |
| Edwards Lifesciences Corporation | $15.24 | 2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Zyla Life Sciences, INC. | $11.91 | 2019 | |
| Hikma Pharmaceuticals USA | $11.73 | 2019 | |
| Medicure Pharma INC. | $10.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$1,344.73 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gerald Hill listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.